Longeveron (NASDAQ:LGVN – Get Free Report) is expected to release its earnings data before the market opens on Tuesday, February 25th. Analysts expect Longeveron to post earnings of ($0.36) per share for the quarter.
Longeveron Stock Performance
Shares of NASDAQ:LGVN opened at $1.67 on Tuesday. The firm has a market cap of $24.78 million, a PE ratio of -0.27 and a beta of 0.36. Longeveron has a 52 week low of $0.77 and a 52 week high of $6.40. The firm’s fifty day moving average is $1.71 and its 200-day moving average is $1.98.
Analyst Ratings Changes
LGVN has been the topic of a number of analyst reports. Roth Capital upgraded Longeveron to a “strong-buy” rating in a research report on Thursday, December 5th. Roth Mkm started coverage on Longeveron in a research note on Friday, December 6th. They issued a “buy” rating and a $10.00 price objective on the stock. Finally, HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Longeveron in a research report on Monday, November 25th.
About Longeveron
Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors.
Featured Articles
- Five stocks we like better than Longeveron
- Best Stocks Under $5.00
- Airbnb’s Earnings: Sky High Results, Grounded Guidance?
- What Are Growth Stocks and Investing in Them
- Kyndryl Soars on AI, Cybersecurity Growth—What’s Next?
- Dividend Capture Strategy: What You Need to Know
- Conflicting Signals: Tempus AI’s Stock Market Rally
Receive News & Ratings for Longeveron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Longeveron and related companies with MarketBeat.com's FREE daily email newsletter.
